Company will take a fourth quarter charge of $500,000 due to a 12% reduction in its 1,200-member workforce through terminations and attrition, firm announces Dec. 19. Personnel cuts, which do not target any particular segment or division, are part of a new plan to increase operating efficiencies and reduce overhead. Hauppauge, N.Y.-based company also is streamlining and consolidating administration and operations for its catalog and direct-sales divisions. "Modest" price increases in 2001 on approximately 10% of Twinlab products also should be expected, Twinlab tells its distributors. The firm is currently facing shareholder lawsuits stemming from sales declines and inventory discrepancies (1"The Tan Sheet" Dec. 4, 2000, In Brief)
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Lerodalcibep and palbociclib are among the latest new drugs that the European Medicines Agency has started to review for potential EU marketing authorization.
Country recommends eights new drugs for approval, including six for rare diseases, and also announces macroeconomic policy the pharma industry says would enable some reimbursement prices to be raised.
Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.
